NO20072541L - Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster - Google Patents

Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster

Info

Publication number
NO20072541L
NO20072541L NO20072541A NO20072541A NO20072541L NO 20072541 L NO20072541 L NO 20072541L NO 20072541 A NO20072541 A NO 20072541A NO 20072541 A NO20072541 A NO 20072541A NO 20072541 L NO20072541 L NO 20072541L
Authority
NO
Norway
Prior art keywords
crf
receptor antagonists
pyrazole
alpha
releasing factor
Prior art date
Application number
NO20072541A
Other languages
English (en)
Norwegian (no)
Inventor
Zhiyong Luo
John Edward Tellew
Xiaohu Zhang
Marion Lanier
Manisha Moorjami
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072541(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20072541L publication Critical patent/NO20072541L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072541A 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster NO20072541L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62006004P 2004-10-19 2004-10-19
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound
PCT/US2005/037576 WO2006044958A1 (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists

Publications (1)

Publication Number Publication Date
NO20072541L true NO20072541L (no) 2007-06-25

Family

ID=35395069

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20072541A NO20072541L (no) 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Country Status (21)

Country Link
US (1) US7879862B2 (uk)
EP (2) EP1802627B1 (uk)
JP (2) JP4901744B2 (uk)
KR (2) KR20070088621A (uk)
CN (1) CN101273043B (uk)
AR (2) AR051461A1 (uk)
AU (2) AU2005295353B2 (uk)
BR (1) BRPI0616767A2 (uk)
CA (2) CA2584567C (uk)
CR (1) CR9918A (uk)
EA (1) EA200801000A1 (uk)
GB (1) GB0519957D0 (uk)
IL (1) IL190225A0 (uk)
MA (1) MA29850B1 (uk)
NO (2) NO20072541L (uk)
NZ (1) NZ554082A (uk)
PE (2) PE20060586A1 (uk)
RU (1) RU2007118683A (uk)
TW (2) TW200626599A (uk)
UA (1) UA92756C2 (uk)
WO (2) WO2006044958A1 (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
BRPI0417943A (pt) * 2003-12-22 2007-04-17 Sb Pharmco Inc antagonistas de receptor de crf e métodos relacionados para essa finalidade
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
NZ588376A (en) 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
JP2015516979A (ja) * 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
BR112016016975B1 (pt) 2014-01-21 2022-12-27 Neurocrine Biosciences Inc Usos de um antagonista do receptor crf1 para o tratamento de hiperplasia adrenal congênita e para reduzir níveis de 17-ohp e acth em um paciente
EP3096762B1 (en) * 2014-01-22 2023-06-28 Curovir Ab Pyrazolo[1,5-a]pyrimidines as antiviral compounds
JP7185633B2 (ja) 2017-02-17 2022-12-07 トレベナ・インコーポレイテッド ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
EP0714898B1 (en) 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
BR9707391A (pt) 1996-02-07 1999-07-20 Janssen Pharmaceutica Nv Pirazolpirimidinas como antagonistas de receptor de crf
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
IL127871A0 (en) * 1996-07-24 1999-10-28 Du Pont Pharm Co Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
AU735401B2 (en) 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
CN1542010A (zh) 1998-01-28 2004-11-03 �Ű�ҩƷ��˾ 吡咯并三嗪和嘧啶化合物
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
CA2359041A1 (en) 1999-01-29 2000-08-03 Sumitomo Chemical Co., Ltd. Fat accumulation inhibitory agents
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CN1377355A (zh) * 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
EP1383747B1 (en) 2001-04-30 2008-02-20 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7196111B2 (en) 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
WO2004062665A1 (en) 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
EP1697369A1 (en) 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
BRPI0417943A (pt) 2003-12-22 2007-04-17 Sb Pharmco Inc antagonistas de receptor de crf e métodos relacionados para essa finalidade
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
EP1802621B1 (en) 2004-10-19 2009-05-06 SmithKline Beecham (Cork) Limited Crf receptor antagonists and methods relating thereto
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
EA200801000A1 (ru) 2009-02-27
WO2006044958A1 (en) 2006-04-27
WO2007039264A1 (en) 2007-04-12
EP1934222A1 (en) 2008-06-25
GB0519957D0 (en) 2005-11-09
JP4901744B2 (ja) 2012-03-21
KR20080063760A (ko) 2008-07-07
CN101273043A (zh) 2008-09-24
RU2007118683A (ru) 2008-11-27
AU2005295353B2 (en) 2012-01-12
US7879862B2 (en) 2011-02-01
KR20070088621A (ko) 2007-08-29
NO20081941L (no) 2008-04-23
IL190225A0 (en) 2009-09-22
EP1934222B1 (en) 2012-07-25
CA2584567C (en) 2013-04-30
EP1802627B1 (en) 2012-08-29
WO2006044958A8 (en) 2006-06-08
US20080194589A1 (en) 2008-08-14
JP2009510004A (ja) 2009-03-12
CR9918A (es) 2009-02-03
AU2005295353A1 (en) 2006-04-27
AU2006298995A1 (en) 2007-04-12
CA2584567A1 (en) 2006-04-27
AR051461A1 (es) 2007-01-17
EP1802627A1 (en) 2007-07-04
NZ554082A (en) 2010-12-24
TW200626599A (en) 2006-08-01
AR056104A1 (es) 2007-09-19
JP2008517067A (ja) 2008-05-22
MA29850B1 (fr) 2008-10-03
CN101273043B (zh) 2011-08-03
TW200745121A (en) 2007-12-16
PE20060586A1 (es) 2006-09-20
CA2624699A1 (en) 2007-04-12
PE20070845A1 (es) 2007-08-25
UA92756C2 (uk) 2010-12-10
BRPI0616767A2 (pt) 2011-06-28
AU2006298995B2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
NO20072541L (no) Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
JO2676B1 (en) Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
TNSN05252A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them
NO20071446L (no) Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
WO2007096782A3 (en) Compositions for disorders associated wtth metachromatic cell activation
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
WO2006007540A3 (en) Piperidine derivatives as nk1 antagonists
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
GB0508471D0 (en) Therapeutic agents
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
TW200738641A (en) Pyrazole based LXR modulators
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2005103039A8 (en) 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
NO20090664L (no) Purinderivater som A2A-agonister
JO2525B1 (en) Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2006094934A8 (en) Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application